Lyme disease is a tick-borne infection caused by Borrelia burgdorferi (and related species). In its acute phase, it is typically treated with antibiotics — doxycycline or amoxicillin for 2–4 weeks. Most patients recover fully. But a subset develop persistent symptoms — fatigue, cognitive difficulties, joint pain, neuropathy — that can last months or years. This is variously termed post-treatment Lyme disease syndrome (PTLDS), chronic Lyme disease, or long Lyme.
It is in this chronic, post-treatment phase that patients often turn to complementary therapies, including red light therapy. The question is whether there is any scientific basis for this.
The evidence: let us be direct
There are no published clinical trials examining photobiomodulation for Lyme disease. No RCTs, no controlled studies, no formal case series in peer-reviewed journals. The evidence base is zero.
This does not mean PBM definitely does not help. It means we do not know, and anyone claiming it treats Lyme disease is making a statement unsupported by clinical evidence.
The theoretical rationale
Despite the absence of direct evidence, there are plausible biological mechanisms that explain why some Lyme patients report benefit from PBM. These are theoretical, not proven.
1. Anti-inflammatory effects
PTLDS involves chronic, low-grade inflammation — elevated cytokines, microglial activation in the brain, and persistent immune activation even after the infection has been cleared. PBM’s well-documented anti-inflammatory effects (reducing TNF-alpha, IL-1beta, IL-6, and modulating NF-kappaB signalling) could theoretically reduce this inflammation.
This is the same mechanism by which PBM benefits arthritis, tendonitis, and other inflammatory conditions. If PTLDS symptoms are driven by residual inflammation rather than active infection, anti-inflammatory PBM effects could plausibly provide symptomatic relief.
2. Mitochondrial support
Fatigue is the most common PTLDS symptom. Borrelia infection may impair mitochondrial function, and some researchers have proposed that persistent mitochondrial dysfunction contributes to chronic fatigue post-Lyme.
PBM’s primary mechanism of action — stimulating cytochrome c oxidase in the mitochondrial electron transport chain, increasing ATP production — could theoretically address this. The same rationale applies to PBM for chronic fatigue syndrome (CFS/ME), which shares many symptoms with PTLDS.
3. Neuroprotective effects
Lyme neuroborreliosis can cause cognitive impairment, neuropathy, and brain fog. Transcranial PBM (near-infrared light applied to the skull) has shown some preliminary evidence for neurological conditions including traumatic brain injury and Alzheimer’s disease. The anti-inflammatory and neuroprotective effects could theoretically benefit neurological Lyme symptoms.
4. Pain modulation
Joint pain and neuropathic pain are common in PTLDS. PBM has moderate evidence for pain reduction in other conditions (arthritis, neuropathy, fibromyalgia), and the same analgesic mechanisms could apply to Lyme-related pain.
The parallel to long COVID
Long COVID (post-acute sequelae of SARS-CoV-2, or PASC) shares many features with PTLDS: persistent fatigue, cognitive dysfunction, pain, exercise intolerance, and dysautonomia. The two conditions are increasingly discussed together in the medical literature.
The PBM evidence for long COVID is also very limited. A handful of small, uncontrolled studies and case reports have been published:
Mussttaf et al. (2022) proposed that PBM could benefit long COVID through anti-inflammatory and mitochondrial mechanisms, but this was a hypothesis paper, not a clinical trial.
Some clinics offer PBM as part of multi-modal long COVID rehabilitation programmes, but it is impossible to isolate the contribution of PBM from other concurrent interventions (graded exercise, nutritional support, cognitive rehabilitation).
The shared pathophysiology between PTLDS and long COVID — chronic inflammation, mitochondrial dysfunction, autonomic dysregulation — means that if PBM proves beneficial for one, it may benefit the other. But that “if” is doing enormous heavy lifting.
What patients report (anecdotal)
Patient forums, Lyme disease support groups, and functional medicine practitioners report that some Lyme patients find PBM helpful for:
- Reduced fatigue
- Improved sleep quality
- Less joint and muscle pain
- Better cognitive clarity
- Reduced headache frequency
These reports cannot be dismissed entirely, but they also cannot be attributed to PBM with confidence. Placebo response rates in chronic fatigue and pain conditions are high (30–50% in many trials). Without controlled studies, we cannot determine whether PBM is producing genuine physiological effects or whether patients are experiencing placebo benefit, natural symptom fluctuation, or benefit from other concurrent lifestyle changes.
A cautious protocol (if you choose to try)
Given the lack of direct evidence, no evidence-based protocol exists for Lyme disease. The following is extrapolated from PBM research in related areas (inflammation, pain, fatigue, neuropathy):
Wavelength
- 810–850nm (NIR) — Best tissue penetration, most relevant for deep tissue inflammation, joints, and transcranial applications
- 660nm (red) — Useful for superficial pain and inflammation
For joint and muscle pain
- Apply directly to affected areas
- 20–40 J/cm², 5–10 minutes per area
- Daily or every other day
For fatigue and cognitive symptoms
- Transcranial PBM: 810nm applied to the forehead and temporal areas
- 10–20 J/cm², 10–20 minutes
- 3–5 times per week
- Note: Transcranial PBM has a limited but growing evidence base for other neurological conditions, not Lyme specifically
For general systemic effects
- Full-body panel exposure, 10–15 minutes
- 3–5 times per week
Important caveats
- Do not use PBM instead of antibiotics for acute Lyme disease. Untreated Lyme can progress to serious neurological, cardiac, and joint complications
- Do not stop any prescribed treatment based on PBM use
- If you are on immunosuppressive therapy for Lyme-related autoimmune complications, read our autoimmune page for additional cautions
- Track your symptoms systematically (a simple daily 1–10 rating for fatigue, pain, and cognition) so you can objectively assess whether PBM is making a difference over 4–8 weeks
The bottom line
Red light therapy for Lyme disease is entirely theoretical. There is a plausible biological rationale based on PBM’s anti-inflammatory, mitochondrial, and analgesic mechanisms — but zero clinical trials in Lyme patients. The same applies to long COVID.
If you have PTLDS and wish to try PBM, it is unlikely to cause harm when used alongside medical management. But set realistic expectations: at best, you might see modest improvements in pain, fatigue, and cognition. At worst, you will spend money on a device that provides no measurable benefit beyond placebo.
The Lyme disease community deserves better research, not unfounded promises. Until controlled trials are conducted, PBM remains an unvalidated adjunct for Lyme disease — nothing more.
Find the right device
Compare 20+ red light therapy devices by wavelength, irradiance, and value.
Red Light Therapy for Autism & Seizures
Evidence review: red light therapy for autism & seizures. Research, wavelengths, and protocols.
Red Light Therapy for Autoimmune Conditions
Evidence review: red light therapy for autoimmune conditions. Research, wavelengths, and protocols.
Red Light Therapy for Blood Clots & DVT
Evidence review: red light therapy for blood clots & dvt. Research, wavelengths, and protocols.
Evidence-based RLT updates
No hype, just research. New studies, protocol updates, and device test results in your inbox.